CL2022002592A1 - Uso de agentes para el tratamiento de condiciones respiratorias - Google Patents

Uso de agentes para el tratamiento de condiciones respiratorias

Info

Publication number
CL2022002592A1
CL2022002592A1 CL2022002592A CL2022002592A CL2022002592A1 CL 2022002592 A1 CL2022002592 A1 CL 2022002592A1 CL 2022002592 A CL2022002592 A CL 2022002592A CL 2022002592 A CL2022002592 A CL 2022002592A CL 2022002592 A1 CL2022002592 A1 CL 2022002592A1
Authority
CL
Chile
Prior art keywords
agents
treatment
respiratory conditions
subject
compound
Prior art date
Application number
CL2022002592A
Other languages
English (en)
Inventor
Jay Kanes Stephen
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CL2022002592A1 publication Critical patent/CL2022002592A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan métodos para tratar un síntoma de una condición respiratoria o una enfermedad asociada con un coronavirus, en un sujeto, que comprenden administrar al sujeto una cantidad efectiva de un agente seleccionado del grupo que consiste en el Compuesto 1 y el Compuesto 2, o una sal farmacéuticamente aceptable de los mismos.
CL2022002592A 2020-03-25 2022-09-23 Uso de agentes para el tratamiento de condiciones respiratorias CL2022002592A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062994805P 2020-03-25 2020-03-25
US202062994803P 2020-03-25 2020-03-25
US202063000418P 2020-03-26 2020-03-26
US202063000415P 2020-03-26 2020-03-26
US202063006671P 2020-04-07 2020-04-07
US202063006672P 2020-04-07 2020-04-07
US202063063780P 2020-08-10 2020-08-10
US202063063803P 2020-08-10 2020-08-10

Publications (1)

Publication Number Publication Date
CL2022002592A1 true CL2022002592A1 (es) 2023-04-21

Family

ID=75478347

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002592A CL2022002592A1 (es) 2020-03-25 2022-09-23 Uso de agentes para el tratamiento de condiciones respiratorias

Country Status (15)

Country Link
US (2) US20230414636A1 (es)
EP (1) EP4125921A1 (es)
JP (1) JP2023519241A (es)
KR (1) KR20220157426A (es)
CN (1) CN115551514A (es)
AU (1) AU2021241622A1 (es)
BR (1) BR112022019085A2 (es)
CA (1) CA3176854A1 (es)
CL (1) CL2022002592A1 (es)
CO (1) CO2022013777A2 (es)
IL (1) IL296645A (es)
MX (1) MX2022011804A (es)
PE (1) PE20221911A1 (es)
TW (2) TW202143977A (es)
WO (2) WO2021195297A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014008895A (es) 2012-01-23 2014-11-25 Sage Therapeutics Inc Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
BR112019003637A2 (pt) 2016-08-23 2019-08-06 Sage Therapeutics Inc um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
US20230381125A1 (en) * 2020-09-25 2023-11-30 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
AU2021385335A1 (en) * 2020-11-25 2023-06-29 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2023164387A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024020953A1 (zh) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2243232C2 (ru) 1999-04-29 2004-12-27 Еро-Сельтик С.А. 3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
MX2014008895A (es) 2012-01-23 2014-11-25 Sage Therapeutics Inc Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP4335505A3 (en) 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
JP6542127B2 (ja) 2012-12-18 2019-07-10 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) * 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
TW202235090A (zh) 2014-10-16 2022-09-16 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
EP3250210B1 (en) 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3377070A4 (en) 2015-11-20 2019-07-10 Sage Therapeutics, Inc. COMPOUNDS AND METHOD FOR THEIR USE
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
DK3481845T3 (da) 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
BR112019003637A2 (pt) 2016-08-23 2019-08-06 Sage Therapeutics Inc um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
EP3678670A1 (en) 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
WO2019126741A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US20210139530A1 (en) 2018-02-11 2021-05-13 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
US20210205329A1 (en) * 2018-05-21 2021-07-08 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
TW202005653A (zh) 2018-06-12 2020-02-01 美商賽吉醫療公司 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
US20210177805A1 (en) * 2018-08-22 2021-06-17 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2020185710A1 (en) * 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor

Also Published As

Publication number Publication date
TW202202146A (zh) 2022-01-16
JP2023519241A (ja) 2023-05-10
IL296645A (en) 2022-11-01
PE20221911A1 (es) 2022-12-23
TW202143977A (zh) 2021-12-01
CN115551514A (zh) 2022-12-30
US20230346801A1 (en) 2023-11-02
CA3176854A1 (en) 2021-09-30
KR20220157426A (ko) 2022-11-29
US20230414636A1 (en) 2023-12-28
AU2021241622A1 (en) 2022-10-20
BR112022019085A2 (pt) 2023-01-31
MX2022011804A (es) 2023-03-09
EP4125921A1 (en) 2023-02-08
WO2021195297A1 (en) 2021-09-30
CO2022013777A2 (es) 2022-10-11
WO2021195301A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR119158A1 (es) Tratamientos de angioedema hereditario
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CO5590913A2 (es) Terapia de combinacion antivirica
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
AR119159A1 (es) Tratamientos de angioedema
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
PE20230996A1 (es) Metodo para el tratamiento de afecciones asociadas a covid-19
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX9400040A (es) Composiciones para tratar trastornos respiratorios.
AR122400A1 (es) Uso de agentes para el tratamiento de afecciones respiratorias
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño